Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease, JJ Gomez-Reino… - Annals of the …, 2014 - ard.bmj.com
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …
被引用次数：571 相关文章

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease… - Annals of the …, 2014 - search.proquest.com
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …
[HTML] nih.gov

[HTML][HTML] Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease, JJ Gomez-Reino… - Annals of the …, 2014 - ncbi.nlm.nih.gov
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …
[PDF] psu.edu

[PDF][PDF] Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease, JJ Gomez-Reino… - 2014 - Citeseer
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …
[PDF] kobv.de

[PDF][PDF] Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease, JJ Gomez-Reino… - Annals of the …, 2014 - opus4.kobv.de
Objectives: Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

A Kavanaugh, PJ Mease, JJ Gomez-Reino… - Annals of the …, 2014 - europepmc.org
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …
[PDF] researchgate.net

[PDF][PDF] Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease, JJ Gomez-Reino… - 2014 - researchgate.net
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …
[PDF] uab.edu

[PDF][PDF] Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease, JJ Gomez-Reino… - 2014 - uab.edu
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …
[PDF] bmj.com

[PDF][PDF] Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease, JJ Gomez-Reino… - Annals of the …, 2014 - ard.bmj.com
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

A Kavanaugh, PJ Mease… - Annals of the …, 2014 - providence.elsevierpure.com
Objectives: Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory
mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) …